Oncolytics ready for final step with Reolysin

After a 10-year journey, Oncolytics Biotech (TSX:ONC; NASDAQ:ONCY ) is ready to take the final clinical step with its sole Reolysin drug as a treatment for a broad range of cancers. “Our product has really shown a breadth of activity in a wide variety of cancers that we had hoped it would way back when [...]

Versant ups Patheon to buy

Versant Partners upgraded Patheon (TSX:PTI) to “buy” from “neutral” and raised the 12-month target price to $3.60 from $3.25. The stock is trading at $2.62, down one cent, on Tuesday afternoon. Analyst Doug Loe writes that in addition to Patheon closing a $280 million (U.S.) offering of notes, there are “encouraging signs from peers that [...]

Protox trims size of private placement

Protox Therapeutics (TSX:PRX) has reduced the size of its planned private placement to about $6.5 million from $8 million through the sale of units priced at 45 cents each instead of 55 cents. Each unit consists of one common share of Protox and one-half of a warrant.  Each whole warrant will entitle the holder to [...]

Versant backs iCo interim efficacy data

iCo Therapeutics (TSX-V:ICO) reported interim efficacy data at a medical conference over the weekend from a few patients in its 15-patient Phase 1 diabetic macular edema trial testing its antisense drug iCo-007. Versant Partners analyst Doug Loe writes that the case-study data “showed solid evidence of iCo-007 impact on retinal thickness/macular edema at six months [...]

AEterna’s missed Phase 3 gets ho-hum analyst reaction

Analysts are not surprised that Aeterna Zentaris’ cetrorelix drug candidate missed its primary endpoint in a Phase 3 clinical trial in Europe, matching the disappointing outcome of a similar pivotal trial in the U.S. earlier this year. RBC Capital Markets now expects AEterna (NASDAQ:AEZS; TSX:AEZ) to terminate the cetrorelix program and focus on its other [...]

Versant starts TSO3 at “buy”

Versant Partners initiated coverage of TSO3 (TSX:TOS) with a “buy” and 12-month price target of $2.50 after the maker of ozone-based sterilizers for healthcare markets won FDA approval last week to expand the intended claims of its Sterizone 125L sterilizer.  The stock closed at $1.61 on Friday. Analyst Doug Loe writes that TSO3 is in [...]

Analysts hike Cangene price targets

Versant Partners raised its 12-month price target on Cangene (TSX:CNJ) to $11 from $10 after the drug maker’s fiscal 2009 profit blew through analysts’ forecasts. On Thursday, Winnipeg-based Cangene reported a  profit gain of 102% on revenue 44% higher for the fiscal year ended July 31,  sending its stock price soaring $1.84 to $6.39. Versant [...]

« Previous Page